GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B virus (HBV)-targeted siRNA antiviral JNJ-3989 from Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen. The agreement includes Arrowhead Pharmaceuticals, the original discoverer of the investigational drug, which was initially licensed to Janssen in 2018.
GSK’s Development Plans for JNJ-3989
GSK plans to progress the molecule into Phase II clinical trials next year in combination with its antisense oligonucleotide bepirovirsen. Bepirovirsen is currently in Phase III of development as a potential functional cure for non-cirrhotic patients with chronic hepatitis B (CHB) who are on nucleoside or nucleotide analogue (NA) therapy. This strategic move by GSK aims to enhance its hepatitis B treatment portfolio and provide new treatment options for patients.
Financial Terms and Ongoing Trials
Under the terms of the deal, GSK will provide Janssen and Arrowhead with up to USD 1 billion in upfront and potential milestone payments. GSK will also assume all remaining financial obligations owed to Arrowhead under the original license agreement with Janssen. Furthermore, Janssen will complete all ongoing trials involving JNJ-3989, while Arrowhead remains eligible to receive tiered royalties from the commercialization of the drug.-Fineline Info & Tech
